PROF · XBRL financial data
Profound Medical financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PROF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | 7,199 | 10,680 | 16,098 |
| Revenue from contracts with customers | — | — | — | 5,899 | 9,740 | — |
| Cost of revenue | — | — | — | 2,887 | 3,643 | 4,705 |
| Gross profit | — | — | — | 4,312 | 7,037 | 11,393 |
| Research and development | — | — | — | 14,424 | 16,965 | 20,596 |
| Selling, general and administrative | — | — | — | 18,539 | 23,134 | 32,051 |
| Total operating expenses | — | — | — | 32,963 | 40,099 | 52,647 |
| Operating income (loss) | — | — | — | (28,651) | (33,062) | (41,254) |
| Interest expense | — | — | — | — | 600 | 394 |
| Income tax expense (benefit) | — | — | — | (128) | (2) | 252 |
| Net income (loss) | — | — | — | (28,323) | (27,816) | (42,570) |
| Earnings per share, basic USD per share | — | — | — | 1.34 | 1.12 | 1.41 |
| Earnings per share, diluted USD per share | — | — | — | 1.34 | 1.12 | 1.41 |
| Weighted average shares, basic thousands of shares | — | — | — | 21,183 | 24,766 | 30,233 |
| Weighted average shares, diluted thousands of shares | — | — | — | 21,183 | 24,766 | 30,233 |
| Revenue | 7,304 | 6,873 | 6,681 | 7,199 | — | — |
| Cost of sales | 3,830 | 3,921 | 3,660 | 2,817 | — | — |
| Gross profit | 3,474 | 2,952 | 3,021 | 4,382 | — | — |
| Research and development | 9,912 | 15,277 | 14,690 | 14,377 | — | — |
| Operating profit (loss) | (18,863) | (30,291) | (32,126) | (28,616) | — | — |
| Profit (loss) | (21,622) | (30,699) | (28,669) | (28,569) | — | — |
| Earnings per share, basic USD per share | 1.25 | 1.50 | 1.38 | 1.35 | — | — |
| Earnings per share, diluted USD per share | 1.25 | 1.50 | 1.38 | 1.35 | — | — |
Balance sheet
CSVFiscal years (PROF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | — | — | 46,517 | 26,213 | 54,912 | 59,723 |
| Inventory | — | — | — | 6,989 | 5,801 | 8,238 |
| Total current assets | — | — | — | 41,896 | 69,065 | 76,089 |
| Property and equipment, net | — | — | — | 909 | 425 | 698 |
| Right-of-use asset | — | — | — | 661 | 396 | 184 |
| Total assets | — | — | — | 43,956 | 70,234 | 77,475 |
| Accounts payable | — | — | — | 865 | 1,317 | 1,563 |
| Current portion of long-term debt | — | — | — | 2,104 | 1,737 | — |
| Total current liabilities | — | — | — | 6,368 | 6,565 | 6,075 |
| Long-term debt | — | — | — | 5,000 | 2,924 | 4,499 |
| Lease liability, non-current | — | — | — | 504 | 203 | — |
| Total liabilities | — | — | — | 12,732 | 9,812 | 11,041 |
| Accumulated deficit | — | — | — | (217,354) | (245,170) | (287,740) |
| Total stockholders' equity | — | — | 52,597 | 31,224 | 60,422 | 66,434 |
| Total liabilities and equity | — | — | — | 43,956 | 70,234 | 77,475 |
| Common shares outstanding (cover page) thousands of shares | 20,209 | 20,776 | 20,879 | 21,371 | 30,040 | 36,294 |
| Cash and cash equivalents | 83,913 | 67,152 | 46,517 | 26,213 | — | — |
| Total current assets | 97,742 | 77,125 | 62,024 | 41,896 | — | — |
| Total assets | 104,601 | 86,775 | 64,421 | 43,911 | — | — |
| Total current liabilities | 4,809 | 4,155 | 4,185 | 6,366 | — | — |
| Total liabilities | 7,251 | 6,157 | 12,417 | 12,731 | — | — |
| Total equity | 97,350 | 80,618 | 52,004 | 31,180 | — | — |
| Total equity and liabilities | 104,601 | 86,775 | 64,421 | 43,911 | — | — |
Cash flows
CSVFiscal years (PROF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | — | — | — | (28,323) | (27,816) | (42,570) |
| Stock-based compensation | — | — | — | 3,417 | 2,581 | 5,490 |
| Net cash from operating activities | — | — | — | (22,609) | (23,453) | (38,207) |
| Purchases of property and equipment | — | — | — | — | — | 176 |
| Net cash from investing activities | — | — | — | — | — | (242) |
| Proceeds from issuing common stock | — | — | — | — | 62,106 | 42,436 |
| Repayments of long-term debt | — | — | — | 912 | 2,560 | 290 |
| Net cash from financing activities | — | — | — | 1,756 | 54,696 | 41,138 |
| Net cash from operating activities | (20,574) | (22,360) | (25,800) | (22,297) | — | — |
| Net cash from investing activities | (350) | (593) | — | — | — | — |
| Net cash from financing activities | 87,433 | 5,948 | 7,031 | 1,464 | — | — |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Profound Medical | 38,271 | 2,483 | (11,338)* | 36.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Sight Sciences | 79,753 | 23,388 | (5,663)* | 55.1M | 14.1 quarters | 10-QJun 30, 2026 |
| Stereotaxis | 10,491 | 7,670 | (3,675)* | 100.2M | 2.9 quarters | 10-QJun 30, 2026 |
| Sanara MedTech | 15,421 | 28,137 | 2,038* | 9.2M | — | 10-QJun 30, 2026 |
| Anika Therapeutics | 38,412 | 32,610 | (684)* | 13.4M | 56.2 quarters | 10-QJun 30, 2026 |
| SkinHealth Systems | 206,074 | 72,113 | 2,671* | 130.1M | — | 10-QJun 30, 2026 |
| AVITA Medical | 9,139 | 21,702 | (3,496)* | 30.9M | 3.2 quarters | 10-QJun 30, 2026 |
| Utah Medical Products | 87,528 | 8,529 | 1,383* | 3.2M | — | 10-QJun 30, 2026 |
| Lakeland Industries | 17,901 | 50,139 | (404)* | 9.9M | — | 10-QJul 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.